DIAPH1 Variants in Non-East Asian Patients With Sporadic Moyamoya Disease

Adam J Kundishora1, Samuel T Peters2, Amélie Pinard1

  • 1Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center, Houston.

JAMA Neurology
|June 14, 2021
PubMed
Abstract

Insights

Genetic variants in DIAPH1 are linked to Moyamoya disease (MMD) risk in non-East Asian individuals. This discovery offers new insights into MMD pathogenesis and potential diagnostic approaches.

Area of Science:

  • Genetics
  • Neurology
  • Vascular Biology

Background:

  • Moyamoya disease (MMD) is a progressive vasculopathy causing childhood stroke, characterized by intracranial artery narrowing.
  • The genetic underpinnings of MMD, particularly in non-East Asian populations, remain largely unknown.
  • Previous studies identified familial forms, but the etiology of most sporadic cases is elusive.

Purpose of the Study:

  • To investigate the association of ultrarare de novo and rare, damaging transmitted genetic variants with Moyamoya disease risk.
  • To identify novel genetic factors contributing to MMD pathogenesis, especially in underrepresented ethnic groups.

Main Methods:

  • Whole-exome sequencing was performed on MMD patient-parent trios in a discovery cohort.
  • A validation cohort was used to identify additional rare, large-effect variants in candidate genes.
  • Integrative genomics and in silico modeling were employed to assess variant effects and gene expression patterns.

Main Results:

  • Pathogenic variants in DIAPH1 (mammalian diaphanous-1) were identified in non-East Asian MMD patients, including de novo and rare transmitted variants.
  • Compound heterozygous variants in EVL, a DIAPH1 interactor, were also found.
  • Patients with DIAPH1 or EVL variants exhibited severe MMD and transfusion-dependent thrombocytopenia, with DIAPH1 implicated in vascular cell actin remodeling.

Conclusions:

  • DIAPH1 is identified as a novel risk gene for Moyamoya disease, particularly in sporadic, non-East Asian cases.
  • Impaired vascular cell actin remodeling due to DIAPH1 dysfunction is implicated in MMD pathogenesis.
  • These findings have significant diagnostic and therapeutic implications for Moyamoya disease.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
109
Aneurysm II: Clinical Manifestations and Diagnostic Studies01:21

Aneurysm II: Clinical Manifestations and Diagnostic Studies

Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
64
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
103
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
61
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
126
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
169